Alnylam: Q3 Earnings Snapshot

Alnylam Pharmaceuticals (ALNY) reported Q3 profit of $2.17B, or $15.72 per share, exceeding analyst estimates. Revenue was $1.46B, also surpassing forecasts. Shares are down 42% YTD and 51% over the past year.

Original reporting
Published Oct 29, 2026, 12:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alnylam: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$ALNYBullishMed
01

Why it matters

Beating both adjusted EPS and revenue typically improves near-term sentiment and can reduce perceived execution risk, but traders may still demand forward-looking details to justify re-rating after a steep prior drawdown.

02

Market read

This is a company-specific earnings print with explicit beat metrics, which can drive same-day positioning and volatility.

03

What to watch

The article omits management guidance, segment performance, and any changes in key trial or commercialization milestones, which are often decisive for biotech stocks after an earnings beat.

Relevance 8/10Novelty 8/10Timing: reported on Thursday, immediate post-release trading window

Background

The piece is an earnings snapshot for Alnylam’s third quarter, comparing reported EPS and revenue to analyst expectations from Zacks.

Company-level read

Ticker impact

$ALNYBullishMedium confidence
Context

Alnylam reported Q3 profit of $15.72 per share and adjusted EPS of $16.26, beating Zacks expectations, with revenue of $1.46B also topping forecasts.

Expected impact

Likely upward pressure as the market digests the EPS and revenue beats versus consensus, though follow-through depends on any guidance not included here.

Evidence & confidence

The article provides a first-report earnings snapshot with explicit beat vs analyst estimates, which is typically price-relevant; however, it lacks guidance, margins, or management commentary that often drive the magnitude of the reaction.

Market effects

Reinforces positive sentiment for RNAi drug developers by showing continued commercial execution and earnings resilience.

Limited direct regional spillover beyond US biotech sentiment.

Modest, mainly through broader biotech earnings sentiment rather than global macro.

Counterpoint

A headline EPS beat may not translate into sustained upside if investors focus on forward guidance, pipeline risk, or cash flow details not provided in this snapshot.

Key entities

  • Alnylam Pharmaceuticals Inc.

    RNA interference drug developer reporting Q3 profit, adjusted EPS, and revenue versus analyst expectations.

  • Zacks Investment Research

    Provided the consensus estimates used for the beat/miss comparison.

Related articles

$ALNYHighAI 8/10

Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today

Alnylam Pharmaceuticals (ALNY) stock rose 6.9% after the company shared positive long-term data for AMVUTTRA, reinforcing its cardiovascular benefits. The company also reiterated 2026 guidance and authorized a $1 billion share repurchase program, signaling confidence. Insider and institutional trading activity was noted, with mixed positions.